US Bancorp
MRSN

US Bancorp’s Mersana Therapeutics MRSN Stock Holding History

US Bancorp’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-647
Closed -$23.1K – 4309
2024
Q4 		$23.1K Hold
647
– – ﹤0.01% 3096
2024
Q3 		$30.6K Buy
+647
New +$28.5K ﹤0.01% 2961
2023
Q3 		– Sell
-2
Closed -$174 – 4076
2023
Q2 		$174 Buy
+2
New +$293 ﹤0.01% 3927
2022
Q4 		– Sell
-2
Closed – – 4232
2022
Q3 		$0 Buy
+2
New +$325 ﹤0.01% 4160
2021
Q1 		– Sell
-2
Closed -$2K – 3932
2020
Q4 		$2K Buy
+2
New +$1.11K ﹤0.01% 3589

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return